
    
      This is a study designed to investigate the safety and effectiveness of a medication called
      infliximab (the active drug in (REMICADEÂ®) in adult patients with active ulcerative colitis.
      The purpose of this study is to see if the symptoms of ulcerative colitis are lessened with
      this medication, infliximab, and what dose is needed to do that safely. Patients will receive
      infusions of either 5mg/kg, 10 mg/kg or placebo at weeks 0, 2, 6, and then once every 8 weeks
      thereafter through week 46 for up to 3 years.

      Safety evaluations will be performed at specified intervals throughout the study and will
      consist of laboratory tests, vital signs (such as blood pressure), physical examinations and
      the occurrence and severity of adverse events as well as other study specific procedures.
      Patients will receive infusions of either 5mg/kg, 10 mg/kg or placebo at weeks 0, 2, 6, and
      then once every 8 weeks thereafter through week 46 for up to 3 years.
    
  